142 related articles for article (PubMed ID: 15863265)
1. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
2. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of taxol in human head and neck tumors.
Gan Y; Wientjes MG; Schuller DE; Au JL
Cancer Res; 1996 May; 56(9):2086-93. PubMed ID: 8616855
[TBL] [Abstract][Full Text] [Related]
4. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types.
Reinecke P; Schmitz M; Schneider EM; Gabbert HE; Gerharz CD
Cancer Invest; 2000; 18(7):614-25. PubMed ID: 11036469
[TBL] [Abstract][Full Text] [Related]
6. Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines.
Lui WY; Chang YF; Li LL; Ho LK; Su TL; Chen JY; Liu TY; P'Eng FK; Chi CW
Anticancer Res; 1998; 18(5A):3339-45. PubMed ID: 9858906
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.
Heikaus S; Casliskan E; Mahotka C; Gabbert HE; Ramp U
Apoptosis; 2007 Sep; 12(9):1645-57. PubMed ID: 17610067
[TBL] [Abstract][Full Text] [Related]
8. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Shang D; Ito N; Kamoto T; Ogawa O
Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Int J Oncol; 2005 Jun; 26(6):1563-7. PubMed ID: 15870870
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
Vasey PA; Jones NA; Jenkins S; Dive C; Brown R
Mol Pharmacol; 1996 Dec; 50(6):1536-40. PubMed ID: 8967975
[TBL] [Abstract][Full Text] [Related]
11. [The role of bcl-2 gene family in taxol-mediated apoptosis in BJAB B cell lymphoma cell line].
Zhou X; Xu L; He K
Zhonghua Zhong Liu Za Zhi; 2000 Nov; 22(6):453-5. PubMed ID: 11235561
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
Faried A; Faried LS; Kimura H; Sohda M; Nakajima M; Miyazaki T; Kato H; Kanuma T; Kuwano H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):301-8. PubMed ID: 16028102
[TBL] [Abstract][Full Text] [Related]
13. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
14. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
Ramp U; Dejosez M; Mahotka C; Czarnotta B; Kalinski T; Wenzel M; Lorenz I; Müller M; Krammer P; Gabbert HE; Gerharz CD
Br J Cancer; 2000 Jun; 82(11):1851-9. PubMed ID: 10839301
[TBL] [Abstract][Full Text] [Related]
15. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
[TBL] [Abstract][Full Text] [Related]
16. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
17. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
18. Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro.
Jaakkola M; Rantanen V; Grénman S; Kulmala J; Grénman R
Anticancer Res; 1997; 17(2A):939-43. PubMed ID: 9137431
[TBL] [Abstract][Full Text] [Related]
19. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma.
Sun CQ; Arnold R; Fernandez-Golarz C; Parrish AB; Almekinder T; He J; Ho SM; Svoboda P; Pohl J; Marshall FF; Petros JA
Cancer Res; 2006 Sep; 66(17):8542-9. PubMed ID: 16951166
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
